CA
NZ
UK
AU
IND
US
• Moleculin Biotech reported favorable early efficacy signals for Annamycin in its MIRACLE trial for a high-risk leukemia subgroup.
• The financing stemmed from the conversion of 1.36 million warrants into shares.
• InflaRx (IFRX) is a clinical-stage biotechnology company focused on therapies targeting inflammation-related conditions.
• ChemoCentryx (CCXI) is a biotechnology company associated with therapies targeting inflammatory and autoimmune-related conditions.
• Jyong Biotech has attracted renewed market attention, with some observers asking whether healthcare speculation is helping drive recent moves.
• Perspective Therapeutics has drawn renewed market interest amid growing attention to the radiopharmaceutical field.
• Alaunos Therapeutics (Ticker: TCRT) has attracted renewed attention as a clinical-stage cell-therapy company.
• Hemab Therapeutics (Ticker: COAG) has drawn renewed market interest amid shifting sentiment toward rare-disease biotechnology.
• BillionToOne will occupy approximately 62,659 sq ft of laboratory and office space at 3260 Whipple Road, Union City.
• Cadrenal Therapeutics (NASDAQ: CVKD) appoints John P. Sharp as interim CFO at a flat rate of $455 per hour.
Please wait processing your request...